Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.

[BACKGROUND] Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups.

[METHODS] A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to ensure comprehensive coverage of relevant studies. Key outcomes included overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS) and overall survival (OS).

[RESULTS] A total of 47 studies involving 1346 patients were included in the meta-analysis. Zanubrutinib in previously untreated patients with DLBCL showed a pooled CRR of 79.7% (95% CI 72.7%-86.7%) and a pooled ORR of 95.0% (95% CI 92.6%-97.4%), while the pooled CRR was 44.7% (95% CI 32.4%-56.9%) and the pooled ORR was 67.5% (95% CI 58.0%-77.0%) for the relapsed/refractory patients. For patients with extranodal involvement and elderly patients, the pooled ORRs were 82.3% (95% CI 75.7%-88.9%) and 90.7% (95% CI 85.7%-95.7%), respectively. Pooled analysis of survival curves showed that among previously untreated patients, the median PFS was 31.2 months and median OS was not reached, while the median PFS and OS were 5.9 months and 21.8 months among relapsed/refractory patients, respectively.

[CONCLUSIONS] Zanubrutinib-based regimen achieved encouraging treatment response, especially in specific subtypes of DLBCL, including double expressor, elderly, extranodal involvement, and non-GCB DLBCL.